<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1040544</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.1040544</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Integrative proteomics and metabolomics approach to identify the key roles of icariin-mediated protective effects against cyclophosphamide-induced spermatogenesis dysfunction in mice</article-title>
<alt-title alt-title-type="left-running-head">Fang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2022.1040544">10.3389/fphar.2022.1040544</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fang</surname>
<given-names>Chunyan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1793445/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Yulong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Fang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Fangyue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Yifeng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1829052/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chang</surname>
<given-names>Degui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>You</surname>
<given-names>Yaodong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1934550/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province</institution>, <institution>Hospital of Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Tea Research Institute</institution>, <institution>Sichuan Academy of Agricultural Sciences</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Hospital of Chengdu University of Traditional Chinese Medicine</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/288107/overview">Aiping Lu</ext-link>, Hong Kong Baptist University, Hong Kong SAR, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1244864/overview">Tianxin Zhao</ext-link>, Guangzhou Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/898533/overview">Kan He</ext-link>, Anhui University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Degui Chang, <email>624440310@qq.com</email>; Yaodong You, <email>yyd110@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>1040544</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>09</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>11</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Fang, Ye, Yang, Wang, Shen, Chang and You.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Fang, Ye, Yang, Wang, Shen, Chang and You</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The alkylating antineoplastic agent cyclophosphamide (CP) is known to be toxic to the male reproductive system, but there are no effective prevention or treatment options. The flavonoid icariin (ICA), which is used in Chinese medicine, has been shown to have a number of biological functions, including testicular protection. The current study looked into the protective effects of ICA in preventing CP-induced spermatogenesis dysfunction. The current study looked into the role of ICA in preventing testicular dysfunction caused by CP. For 5&#xa0;days, healthy adult mice were given saline or a single dose of CP (50&#xa0;mg/kg) intraperitoneally (i.p). For the next 30&#xa0;days, mice were given ICA (80&#xa0;mg/kg) by gavage. Animals were euthanized 12&#xa0;h after receiving ICA, and testes were removed for biochemical, histopathological, sperm evaluation, and transmission electron microscope analysis (TEM). We also investigated the potential biological effects of ICA on CP-induced spermatogenesis dysfunction in mice using an integrated proteomic and metabolomic approach. The levels of 8309 proteins and 600 metabolites were measured. The majority of the differential proteins and metabolites were found to be enriched in a variety of metabolic pathways, including the PI3K-Akt signaling pathway, necroptosis, the mTOR signaling pathway, glycerophospholipid metabolism, and ABC transporters, implying that ICA may have molecular mechanisms that contribute to CP-induced spermatogenesis dysfunction in the testis. Taken together, these findings show that ICA effectively reduces testis injury, implying that ICA may have a role in male infertility preservation.</p>
</abstract>
<kwd-group>
<kwd>cyclophosphamide</kwd>
<kwd>spermatogenesis dysfunction</kwd>
<kwd>icariin</kwd>
<kwd>proteomic</kwd>
<kwd>metabolomic</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Cancer is one of the deadly diseases of the world (<xref ref-type="bibr" rid="B8">Fusco et al., 2021</xref>). With the advancement of diagnosis and treatment technology, the survival rate of many cancers has increased dramatically in recent years. Cancer has been treated in a variety of ways, including surgery, chemotherapy, and drugs. CP is one of the most effective and widely used anticancer drugs ever developed (<xref ref-type="bibr" rid="B3">Balow et al., 1987</xref>). It is commonly used to treat sarcomas, leukemias, breast and prostate cancers, neuroblastoma, lymphoma, and multiple myeloma (<xref ref-type="bibr" rid="B20">Ludeman, 1999</xref>; <xref ref-type="bibr" rid="B23">Pagnoux, 2016</xref>). It is also used to treat granulomatosis with polyangiitis, nephrotic syndrome, organ transplant rejection, and a variety of other diseases (<xref ref-type="bibr" rid="B15">Kern and Kehrer, 2002</xref>; <xref ref-type="bibr" rid="B2">Ahmed et al., 2015</xref>). However, the gonadal failure caused by CP is a major issue, particularly in males.</p>
<p>The primary pharmacological activity of CP, a cyclic phosphoramide ester, is to destroy the ability of all cells within its reach to grow and reproduce by cross-linking DNA strands (<xref ref-type="bibr" rid="B32">Vernet et al., 2004</xref>). Because of the presence of uninterrupted cell division, the reproductive system is extremely sensitive to CP (<xref ref-type="bibr" rid="B31">Trasler and Robaire, 1988</xref>). CP causes testicular and epididymal tissue damage in male subjects, resulting in low testosterone levels, oligospermia, and asthenospermia (<xref ref-type="bibr" rid="B10">Ghobadi et al., 2017a</xref>). CP administration in adult male rats decreases testicular weight and modifies the expression of stress response genes in the testis, according to animal studies (<xref ref-type="bibr" rid="B1">Aguilar-Mahecha et al., 2002</xref>). Exposure to CP has been shown to destroy genomic structure and increase lipid preoxidation (<xref ref-type="bibr" rid="B11">Ghobadi et al., 2017b</xref>). However, our understanding of the molecular mechanisms underlying CP toxicity in the testis remains limited.</p>
<p>ICA is a primary bioactive substance derived from the Chinese medicinal herb <italic>Epimedium</italic>. Previous research has shown that ICA has a diverse set of biological and pharmacological properties, including anti-inflammation, anti-tumor, anti-depression, anti-aging, and reproductive system protection (<xref ref-type="bibr" rid="B17">Kong et al., 2015</xref>). By regulating the expression of steroidogenic acute regulatory protein (StAR) and peripheral type benzodiazepine receptor, ICA can significantly increase sperm counts and testosterone levels in the male reproductive system (PBR). In adult male mice, ICA could improve sexual function by regulating the PI3K/AKT/eNOS/NO signaling pathway (<xref ref-type="bibr" rid="B5">Derosa et al., 2018</xref>). Furthermore, animal studies demonstrated that ICA administration prevented testicular dysfunction caused by di (2-ethylhexyl) phthalate (DEHP) by lowering ROS levels in Leydig cells (<xref ref-type="bibr" rid="B28">Sun et al., 2019</xref>). These findings suggest that ICA may play a role in male fertility preservation.</p>
<p>In this paper, we used a CP-induced spermatogenesis dysfunction mouse model to investigate the protective role of ICA on spermatogenesis dysfunction. Because little is known about the effects of ICA on spermatogenesis dysfunction, we investigated the proteome and metabolome of testis exposed to CP and/or treated with ICA to investigate potential mechanisms.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Animals and treatments</title>
<p>Adult male Kunming mice weighing 18&#x2013;22&#xa0;g were acquired from Chengdu Dossy Experimental Animals CO., Ltd. in Chengdu, China, and raised at the Animal Center of Chengdu University of Traditional Chinese Medicine, Chengdu, China. With forced air circulation, a 12-h light/dark cycle, a controlled room temperature of 22&#xb0;C, and fresh food and water, all animals were housed in an animal cabinet. All animal protocols were authorized by Chengdu University of Traditional Chinese Medicine&#x2019;s Animal Care Committee and adhered to the rules and standards in effect at the time by our Institutional Animal Ethics Committee (Ethics committee approval document number: 20211309A).</p>
<p>All of the mice were randomly assigned to one of three groups (<italic>n</italic> &#x3d; 10): normal control (Ctrl group), CP only (CP group), or CP and ICA (ICA group). The control mice were given intraperitoneal injections of normal saline (NS) on a daily basis. For 5&#xa0;days, the male mice (model) were injected with 50&#xa0;mg/kg/d CP (<italic>via</italic> NS as the carrier) to induce testis injury. NS was administered to the Ctrl and CP groups over the next 30&#xa0;days. The ICA group received an 80&#xa0;mg/kg/d dose of ICA (Sichuan ChemConst Biotechnology Co., Ltd., China, lot number CONST210202, ICA&#x3e;98%) intravenously for 30&#xa0;days. All mice were euthanized by exsanguination under urethane anesthesia after treatment. The testis and epididymis were then removed and weighed, and the gonadal index was calculated using the following formula: Testicular or epididymal weight (mg)/body weight (g) &#x3d; gonadal index (mg/g). Each mouse&#x2019;s left epididymis was cut into pieces for sperm collection. The quality of the sperm was assessed and recorded using a computer-aided semen analyser (Beijing Suijia Medical Instrument) and manually. The left testis was severed. Half of the testis was fixed in 4% paraformaldehyde for histologic examination, while the other half was fixed in 3% glutaraldehyde for transmission electron microscopy (TEM). The appropriate testes were kept at &#x2212;80&#xb0;C until use.</p>
</sec>
<sec id="s2-2">
<title>Histologic evaluation</title>
<p>Light microscopy was used to examine paraffin-embedded testicular tissues that had been sectioned to a thickness of 5&#xa0;&#x3bc;m, stained with hematoxylin and eosin (H&#x26;E), and observed. A seminiferous tubule is scored according to its histological characteristics with Johnsen&#x2019;s scoring system. There is no seminiferous epithelium in Score 1, there are no germinal cells, only Sertoli cells are present in Score 2, only spermatogonia are present in Score 3, and hardly any spermatocytes are present in Score 4; the score 5 indicates that there are many spermatocytes; the score 6 indicates that there are few early spermatids; the score 7 indicates that there are many early spermatids; A score of 8 indicates spermatogenesis is impaired, there are fewer late spermatids, disorganized epithelium, and a score of 10 indicates spermatogenesis is complete. (<xref ref-type="bibr" rid="B29">Takahashi et al., 2021</xref>).</p>
</sec>
<sec id="s2-3">
<title>Transmission electron microscopy</title>
<p>New gonadal tissues were prepended with 3% glutaraldehyde, then postfixed in 1% osmium tetroxide, dehydrated in series acetone, and embedded after being infiltrated in Epox 812 for an extended period of time. Icluding sections were stained with methylene blue, and ultrathin sections were stained with uranyl acetate and lead citrate. The sections were examined using a JEM-1400-FLASH Transmission Electron Microscopy (TEM).</p>
</sec>
<sec id="s2-4">
<title>Data independent acquisition mode for proteomic analysis</title>
<p>SDS lysis buffer (8&#xa0;M urea, 1% SDS), containing an appropriate protease inhibitor, was used to extract proteins. The protein was quantified using the BCA method. We start taking an equivalent amount of each sample pool&#x2019;s trypsin-digested peptides and suction dry them before rehydrating them in UPLC loading buffer (Phase A: 2% acetonitrile, pH 10; Phase B: 80% acetonitrile, pH 10). The blended peptides were separated using Vanquish Flex binary UHPLC chromatography (Thermo, United States) with an Acquity UPLC BEH C18 Column (1.7&#xa0;&#x3bc;m, 2.1&#xa0;mm 150&#xa0;mm, Waters, United States). From the mixed sample, 28 fractions were extracted. In brief, the C18-reversed phase column (75&#xa0;&#x3bc;m &#xd7; 25&#xa0;cm, Thermo, United States) was equilibrated with solvents A (2% ACN, 0.1% formic acid) and solvents B (80% ACN, 0.1% formic acid). At a flow rate of 300&#xa0;nL/min, the tryptic peptides were separated.</p>
<p>To automatically switch between full scan MS and MS/MS acquisition, the Q Exactive HF-X instrument was configured to data-dependent acquisition mode (DDA). To automatically switch between full scan MS and MS/MS acquisition, the Q Exactive HF-X instrument was configured to data-independent acquisition mode (DIA). All precursor ions were then chosen for fragmentation by higher-energy collision dissociation in the collision cell following a survey of full scan MS spectra (m/z 300&#x2013;1500). DIA was carried out using a variable isolation window, with each window overlapping by 1&#xa0;m/z, for a total of 40 windows. High level of confidence peptides were employed for protein identification documents by setting a target false discovery rate (FDR) threshold of 1% at the peptide level. For protein identification, only proteins with at least one distinct peptide were used. Spectronaut (Biognosys AG, Version 14) was used to analyze the DIA data files, with the retention time prediction type set to dynamic iRT. Spectronaut 14 determined data extraction based on extensive mass calibration. Spectronaut uses iRT calibration and gradient stability to constantly find the best extraction window.</p>
</sec>
<sec id="s2-5">
<title>Metabolomic analysis</title>
<p>The metabolites were isolated by using a 400&#xa0;&#x3bc;l methanol:water (4:1, v/v) olution and 0.02&#xa0;mg/mL L-2-chlorophenylalanin as an endogenous control. The samples were reconstitute in a 100&#xa0;&#x3bc;l loading solution of acetonitrile:water (1:1, v/v) for UHPLC-MS/MS analysis. In order to create a pooled quality control sample (QC), equal volumes of each sample were combined as part of the system conditioning and quality control process. Similar to how the analytic samples were evaluated and disposed of, the QC samples were also. It helped to represent the whole sample set and was injected at regular intervals (every eight samples) to check on the stability of the analysis.</p>
<p>Thermo Fisher Scientific&#x2019;s UHPLC-Q Exactive HF-X system was performed using for LC-MS analysis. Thermo UHPLC-Q Exactive HF-X Mass Spectrometer with an electrospray ionization (ESI) source that could operate in positive or negative ion mode was used to acquire the mass spectrometric data. Data was gathered using the Data Dependent Acquisition (DDA) technique. The mass range used for the detection was 70&#x2013;1050&#xa0;m/z.</p>
<p>Following the completion of the mass spectrometry detection, the raw LC/MS data is preprocessed by Progenesis QI (Waters Corporation, Milford, United States) software, and it exports a three-dimensional data matrix in CSV format. The data matrix was then deredundant and peak pooled. HMDB (<ext-link ext-link-type="uri" xlink:href="http://www.hmdb.ca/">http://www.hmdb.ca/</ext-link>), Metlin (<ext-link ext-link-type="uri" xlink:href="https://metlin.scripps.edu/">https://metlin.scripps.edu/</ext-link>), and Majorbio Database were used to search for and identify metabolites at the same time. Following the database search, the data is uploaded to the Majorbio cloud platform (<ext-link ext-link-type="uri" xlink:href="https://cloud.majorbio.com">https://cloud.majorbio.com</ext-link>) for analysis. At least 80% of the samples had metabolic characteristics that were maintained. Following filtering, each metabolic characteristic was standardized by sum, and minimum metabolite values were imputed for particular samples whose metabolite levels were below the lower threshold for quantification. In order to minimize errors brought on by sample preparation and instrument instability, the response strength of the sample mass spectrum peaks was standardized using the sum normalization method, and the normalized data matrix was created. Simultaneously, variables exhibiting RSDs greater than 30% of QC samples were eliminated, and the final data matrix for further investigation was generated using log10 logarithmization.</p>
</sec>
<sec id="s2-6">
<title>Bioinformatics analysis</title>
<p>For detecting correlation between testis tissue at different altitudes, R packages were used to perform principal component analysis on quantified proteins. The Q value (FDR) threshold for the precursor and protein levels was set at 1%. For quantification, the intensities of the six peptides with the highest intensities were chosen. Differentially expressed proteins (DEPs) were identified when the fold change (FC) was greater than 1.2 or less than 0.83 and <italic>p</italic>-value &#x3c;0.05 (Student&#x2019;s t test). Additionally, the Mfuzz tool was utilized to classify the DEPs based on their differential expression level administration of CP and ICA (<xref ref-type="bibr" rid="B9">Futschik and Carlisle, 2005</xref>). Principal component analysis (PCA) and orthogonal least partial squares discriminant analysis (OPLS-DA), as well as 7-cycle interactive validation, were carried out using the R package ropls (Version 1.6.2). Differentially expressed metabolites were found when FC &#x3e; 1 or FC &#x3c; 1, VIP &#x3e;1 (OPLS-DA) and <italic>p</italic>-value &#x3c;0.05 (Student&#x2019;s t test) were present. To determine the functions of the proteins and metabolites, they were annotated against Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). In order to identify whether a collection of metabolites occurred in a function node, enrichment analysis was frequently performed. A single metabolite annotation analysis was supposed to lead to a group of metabolite annotation analyses. Scipy stats (Python packages) (<ext-link ext-link-type="uri" xlink:href="https://docs.scipy.org/doc/scipy/">https://docs.scipy.org/doc/scipy/</ext-link>) was used to find statistically substantially enriched pathways using Fisher&#x2019;s exact test.</p>
</sec>
<sec id="s2-7">
<title>RNA extraction and RT-PCR</title>
<p>The MicroElute Total RNA kit (Omega) was used to isolate total RNA from testes. To synthesize cDNA, we used the PrimeScriptTM RT Reagent Kit with gDNA Eraser (TaKaRa) with 1 ug total RNA. An analyzetikjena qTOWER3G system and a Yeasen SYBR Green Master Mix were used for RT-PCR. The Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used as an internal reference. The 2<sup>&#x2212;&#x394;&#x394;CT</sup> method was used to calculate the effects of each experiment independently, with three biological replicates. A list of primers is provided in <xref ref-type="sec" rid="s11">Supplementary Table S12</xref>.</p>
</sec>
<sec id="s2-8">
<title>Statistical analysis</title>
<p>A statistical analysis was carried out using the GraphPad Prism 7 (GraphPad Software). The data are presented as the mean &#xb1; standard error (SE). We used Student&#x2019;s t-test to compare two sets of data. The statistical significance level was set at <italic>p</italic> &#x3c; 0.05; &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>ICA administration protected the reproduction organ in the CP-induced spermatogenesis dysfunction mice model</title>
<p>To explore whether ICA could protect the reproduction system in male mice, we first characterized the testis size from different groups. The testis size of the CP group was significantly smaller than that of the control mice, as shown in <xref ref-type="fig" rid="F1">Figure 1A</xref>. After 30&#xa0;days of ICA treatment (80&#xa0;mg/kg/d), the ICA group&#x2019;s testis size was significantly larger than the CP group&#x2019;s. The reproductive organ cofficient (testis or epididymis) of ICA-treated male mice was significantly higher when compared to CP-exposed male mice (<xref ref-type="fig" rid="F1">Figures 1B,C</xref>). Seminiferous tubules in the CP group had a normal architecture with a circular outline or elliptocytosis, and spermatocytes had a normal structure with no obvious abnormality, according to histological analyses (<xref ref-type="fig" rid="F1">Figure 1D</xref>). In the CP group, however, the testes showed a disruption of the framework of the seminiferous tubules as well as a large number of vacuoles (<xref ref-type="fig" rid="F1">Figure 1D</xref>). After CP administration at a dose of 80&#xa0;mg/kg, testicular tissue appears restored with normal cell morphology of seminiferous tubules and spermatocytes when compared to the CP group (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Further, the Johnsen scores of testes in the ICA-treated mice were significantly higher than those in the CP group (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Protective effects of ICA on the CP-induced testicular damage mice model. <bold>(A)</bold> Gross morphology of the testis. <bold>(B)</bold> The effect of ICA on the testis coefficient. <bold>(C)</bold> The effect of ICA on the epididymis coefficient. <bold>(D)</bold> Representative images of H&#x26;E staining (100 &#xd7; and 400 &#xd7;) of the testis from different groups as indicated (<italic>n</italic> &#x3d; 8). <bold>(E)</bold> ICA increases sperm counts induced by CP in mice. <bold>(F)</bold> ICA attenuates sperm deformity in male mice. <bold>(G)</bold> ICA improved sperm motility. <italic>p</italic> &#x3c; 0.05 was considered statistical difference (<italic>n</italic> &#x3d; 8). <bold>(H)</bold> The ultrastructural changes of testis were observed under TEM from different groups (<italic>n</italic> &#x3d; 3). BM, basement membrane; SG, spermatogonia; S, spermatid; SC, Sertoli cells; PS, primary spermatocyte. The black arrow indicates spermatogonia.</p>
</caption>
<graphic xlink:href="fphar-13-1040544-g001.tif"/>
</fig>
<p>Furthermore, the significant difference in sperm count, sperm deformity, and sperm motility between the CP-treated and other groups demonstrated harm to spermatogenesis. Sperm count and motility were significantly higher in the ICA-treated (80&#xa0;mg/kg) mice than in the CP-exposed mice (<xref ref-type="fig" rid="F1">Figures 1E,F</xref>). Furthermore, the ICA group had significantly lower sperm deformity rates than the CP group (<xref ref-type="fig" rid="F1">Figure 1G</xref>). In addition, CP causes ultrastructural changes in the testis. In the control group, the spermatogonia were flat oval, and the spermatogonia nuclei were abundant but evenly distributed (<xref ref-type="fig" rid="F1">Figure 1H</xref>). However, CP administration resulted in spermatogonial damage, including severely condensed nuclei and little dark cytoplasm. The spermatogenic epithelium of the testis in the ICA group was similar to that in the control group, according to TEM (<xref ref-type="fig" rid="F1">Figure 1H</xref>). These findings suggested that mice given ICA (80&#xa0;mg/kg) could significantly reduce the sperm deformity caused by CP.</p>
</sec>
<sec id="s3-2">
<title>Proteomic and metabolomic profiling of mouse testis</title>
<p>We performed proteomic and metabolomic analyses of mouse testis tissue to better understand the molecular mechanisms underlying ICA&#x2019;s therapeutic effects on CP-induced spermiogenesis damage (<xref ref-type="fig" rid="F2">Figure 2A</xref>). In this study, the data-independent acquisition mass spectrometry (DIA-MS) identification technology was used. The samples from three different groups could be well separated using principal component analysis (PCA) (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>). The DIA quantitative proteomics analysis identified 11,051 peptides (<xref ref-type="fig" rid="F2">Figure 2B</xref>) and 8309 highly reliable proteins in all 9 samples (three groups with three technical replicates each) (<xref ref-type="fig" rid="F2">Figure 2B</xref>). 5614 (60%) of the 8309 proteins had two or more unique peptides (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Overview of the testis proteomics and metabolimics analysis. <bold>(A)</bold> Experiment Workflow. Three groups&#x2014;The Ctrl group injected with Normal saline (NS) (<italic>n</italic> &#x3d; 10), Mod group injected with cyclophosphamide (CP) (<italic>n</italic> &#x3d; 10), ICA group injected with cyclophosphamide in building models of spermatogenesis dysfunction (<italic>n</italic> &#x3d; 10), were used in this study. The ICA treatment group to 80&#xa0;mg/(kg.d) ICA irrigation stomach for 30&#xa0;days. The normal and the model groups each received an equivalent NS. The testis tissue was obtained for omic platforms applied and analysis. <bold>(B)</bold> Distribution of peptide number in three groups. <bold>(C)</bold> Number of characterized metabolites in the Ctrl, CP and ICA samples. <bold>(D)</bold> Principal component analysis (PCA) of the quantified metabolites for each sample.</p>
</caption>
<graphic xlink:href="fphar-13-1040544-g002.tif"/>
</fig>
<p>The raw metabolomic data were collected using LC/MS methods. There were 7780 peacks extracted in total. In all 24 samples (three groups with eight technical replicates each), we found 402 and 198 features in the positive and negative modes, respectively (<xref ref-type="fig" rid="F2">Figure 2C</xref>). To assess system stability at the global metabolomic level, unsupervised PCA was used. The PCA plot showed that the control testis were clearly separated from the CP and ICA testis, indicating that the LC-MS system was stable (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p>
</sec>
<sec id="s3-3">
<title>Identification of proteome changes in Ctrl, CP, and ICA mice testis</title>
<p>To identify differentially expressed proteins (DEPs) in the testis between the control group (Ctrl), cyclophosphamide-induced spermatogenesis dysfunction group (CP), and icariin group (ICA), proteins with an adjusted <italic>p</italic>-value of 0.05, FC &#x3e; 1.2 (up-regulated), or FC &#x3c; 0.83 (down-regulated) were considered significantly DEPs. When the CP group was compared to the Ctrl group, 468 DEPs were found, including 174 up-regulated proteins and 294 down-regulated proteins (<xref ref-type="fig" rid="F3">Figure 3A</xref>). While 351 DEPs were chosen, 174 up-regulated and 177 down-regulated proteins were found in ICA samples compared to CP samples (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Proteomic data revealed that 574 proteins were differentially expressed in the ICA group versus the Ctrl group, with 222 up-regulated proteins and 352 down-regulated proteins (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Then, we cross-matched these DEPs from the Ctrl/CP, ICA/CP, and Ctrl/ICA groups and discovered 61 overlapped proteins (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>), indicating that ICA may play a role in spermatogenesis dysfunction treatment by regulating these 61 proteins.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Quantitative proteomic analysis of testis in Ctrl, CP, and ICA mice. <bold>(A)</bold> Volcano plot of DEPs in destructive testis induced by CP compared to the control testis. <bold>(B)</bold> Volcano plot showing DEPs in testis treated with ICA compared to the destructive testis. <bold>(C)</bold> Volcano plot comparing DEPs between ICA-treated testis and control testis. <bold>(D)</bold> Dysregulated proteins in different groups shown as a heatmap. <bold>(E)</bold> The expression trends of proteins in ten sub-clusters. <bold>(F)</bold> The top 20 enriched GO terms of dysregulated proteins. The <italic>x</italic>-axis indicates the enrichment factor (RichFactor) which represents the number of DEPs annotated for each pathway divided by the number of all identified proteins annotated to the same pathway. A greater RichFactor indicates greater enrichment. The <italic>Y</italic>-axis shows the match ratio of GO terms. Bubble size represents the number of differentially expressed proteins in the pathway, and color indicates enrichment significance. <bold>(G)</bold> Top 20 dysregulated protein KEGG pathways.</p>
</caption>
<graphic xlink:href="fphar-13-1040544-g003.tif"/>
</fig>
<p>We performed a hierarchical cluster analysis based on three groups to systematically invistate the protein expression changes among the three groups (<xref ref-type="fig" rid="F3">Figure 3D</xref>). According to the findings, all DEPs were classified into ten clusters with distinct expression trends (<xref ref-type="fig" rid="F3">Figure 3E</xref>). Among the ten clusters, proteins in clusters 4 (C4), C6, and C7 were down-regulated in the CP group when compared to the Ctrl group, but up-regulated in the ICA group when compared to the CP group. A total of 262, 23, and 74 proteins were classified as C4, C6, and C7, respectively (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>). Given that the ICA could increase protein expression in these three clusters, we hypothesized that forced exoression of these three protein clusters could compensate for spermatogenesis damage in the testis.</p>
<p>GO and KEGG pathway enrichment analyses were performed to better understand the function of these DEPs. The biological process (BPmost)&#x2019;s significantly enriched GO terms were monosaccharide metabolic process, nucleotide biosynthetic process, organophosphate biosynthetic process, and carbohydrate metabolic process (<xref ref-type="fig" rid="F3">Figure 3F</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S2</xref>). The main enriched GO terms of molecular function were primary active transmembrane transporter activity, active transmembrane transporter activity, ligase activity, and ATP-dependent activity (MF). Furthermore, the ribosome, cell junction, synapse, and catalytic complex were the main representative GO terms of the cellular component (CC). The KEGG pathway enrichment results revealed that metabolic pathways, neurodegeneration-multiple diseases pathways, Amyotrophic lateral sclerosis pathways, and so on were the most significantly enriched (<xref ref-type="fig" rid="F3">Figure 3G</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S3</xref>). These findings suggest that metabolic and disease-related pathways are important for cariin-mediated protection against spermatogenesis dysfunction in mice.</p>
</sec>
<sec id="s3-4">
<title>Screening and characterization of differential matabilites in testis</title>
<p>The levels of testis metabolites were measured using LC-MS/MS to further evaluate the treatment of ICA in CP-induced spermatogenesis dysfunction mice. Eight biological replicates were investigated. PCA was used to cluster &#x201c;Ctrl vs. CP&#x201d;, &#x201c;CP vs. ICA&#x201d;, and &#x201c;Ctrl vs. ICA&#x201d;. The PCA revealed a clear distinction between the three groups (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>). Furthermore, the OPLS-DA score plot revealed a significant separation effect between groups (<xref ref-type="sec" rid="s11">Supplementary Figure S4</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Metabolomics analyses revealed metabolic changes in ICA treatment of dysfunctional testis induced by CP. <bold>(A)</bold> PCA plots of &#x201c;Ctrl vs. CP&#x201d; in positive (left) and negative (right) ion scanning mode. <bold>(B)</bold> PCA plots of &#x201c;CP vs. ICA&#x201d; in positive (left) and negative (right) ion scanning mode. <bold>(C)</bold> PCA plots of &#x201c;Ctrl vs. ICA&#x201d; in positive (left) and negative (right) ion scanning mode. <bold>(D)</bold> Volcano map of &#x201c;Ctrl&#x201d; vs. CP&#x201d;. <bold>(E)</bold> A volcano map comparing &#x201c;CP&#x201d; and &#x201c;ICA&#x201d;. <bold>(F)</bold> An overview of the volcano map of &#x201c;Ctrl&#x201d; versus &#x201c;ICA&#x201d;. <bold>(G)</bold> The enriched top 20 KEGG pathways of &#x201c;Ctrl vs. CP&#x201d;. <bold>(H)</bold> The enriched top 20 KEGG pathways of &#x201c;CP vs. ICA&#x201d;. <bold>(I)</bold> The enriched top 20 KEGG pathways of &#x201c;Ctrl vs. ICA&#x201d;.</p>
</caption>
<graphic xlink:href="fphar-13-1040544-g004.tif"/>
</fig>
<p>VIP and <italic>p</italic> values are the most commonly used criteria for accumulating potential metabolites. Significant metabolic perturbations between the two groups were defined as VIP &#x3e;1 from OPLS-DA and <italic>p</italic>-value &#x3c;0.05 from Student&#x2019;s t-test. Furthermore, fold-change &#x3e;1 indicated that the metabolite was trending upward, whereas fold-change &#x3c;1 indicated a trending downward. As a result, 231 (&#x201c;CP vs. Ctrl&#x201d;) metabolites were obtained, with 118 increased and 113 decreased (<xref ref-type="fig" rid="F4">Figure 4D</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S4</xref>); ICA exposure resulted in 208 (&#x201c;ICA vs. CP&#x201d;) altered metabolites, with 67 increased and 141 decreased metabolites (<xref ref-type="fig" rid="F4">Figure 4E</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S5</xref>). Furthermore, 67 up-regulated metabolites and 131 down-regulated metabolites were detected in the testis following the ICA challenge compared to the Ctrl group (<xref ref-type="fig" rid="F4">Figure 4F</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S6</xref>).</p>
<p>The KEGG pathways were enriched in the differential metabolites of the three comparison groups. According to the KEGG analysis, CP influenced Alanine, Aspartate, and Glutathione metabolism, Beta-Alanine metabolism, Arginine and Proline metabolism, and Sphingolipid metabolism (<xref ref-type="fig" rid="F4">Figure 4G</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S7</xref>). The metabolism of Sphingolipids, Alanine, Aspartate, and Glutamate, Glutathione, Amino sugar and nucleotide sugar, Arginine, and Proline were modulated by ICA treatment (<xref ref-type="fig" rid="F4">Figure 4H</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S8</xref>). Furthermore, CP conduction was found to regulate Sphingolipid metabolism, Glutathione metabolism, Alanine, aspartate, and glutamate metabolism, Glycerolipid metabolism, and Arginine and proline metabolism (<xref ref-type="fig" rid="F4">Figure 4I</xref>; <xref ref-type="sec" rid="s11">Supplementary Table S9</xref>). These findings show that the metabilisms of Alanine, Aspartate and glutamate, and Arginine and proline are associated with ICA&#x2019;s protective effect on spermatogenesis impairment in the testis.</p>
</sec>
<sec id="s3-5">
<title>Interative analysis of proteomics and metabonomics datasets derived from tesis of different groups</title>
<p>The KEGG pathways of identified dysregulated proteins and metabolites were used to draw Venn diagrams, which revealed that there were 94, 76, and 79 commonly enriched pathways from the Ctrl vs. CP and ICA vs. CP, respectively (<xref ref-type="fig" rid="F5">Figure 5A</xref>). The most significantly enriched pathways were selected as the key pathway of ICA in the treatment of spermatogenesis dysfunction in mice, including PI3K-Akt signaling pathway, Necroptosis, mTOR signaling pathway, Glycerophospholipid metabolism, and ABC transporters (<xref ref-type="fig" rid="F5">Figure 5B</xref>). In <xref ref-type="fig" rid="F5">Figure 5C</xref>, as an example of pathway level changes, we show protein and metabolite changes in the Necroptosis pathway. The pathway analysis revealed that CP induced the up-regulation of expression of TRAF25, CypA, IAPs, Casp8, USP21, Hsp90, CaMKII, and CypD on testis in mice. Nevertheless, ICA could inhibit expression of TRAF25, FAF, USP21, ESCRT-III, and CypD to protect testis tissue. Moreover, qRT-PCR results confirmed that the mRNA levels of these genes significantly increased after exposure to CP and reduced after treating with ICA (<xref ref-type="sec" rid="s11">Supplementary Figure S5</xref>). This indicate ICA administration effectively reduces Necroptosis expression to improve the testis morphology of CP-induced injury in testis tissue.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Enriched pathways from the combined analysis of proteomics and metabolomics data. <bold>(A)</bold> Venn diagrams illustrating the number or protein and metabolite pathways significantly changed in &#x201c;Ctrl vs. CP&#x201d; and &#x201c;CP vs. ICA&#x201d;. <bold>(B)</bold> The enriched KEGG pathways in &#x201c;Ctrl vs. CP&#x201d; and &#x201c;CP vs. ICA&#x201d;, which were expressed at both the protein and metabolite level. <bold>(C)</bold> Protein and metabolite modifications in the necroptosis pathway.</p>
</caption>
<graphic xlink:href="fphar-13-1040544-g005.tif"/>
</fig>
<p>
<xref ref-type="sec" rid="s11">Supplementary Data</xref> of <xref ref-type="sec" rid="s11">Supplementary Tables S10, S11</xref> contain all of the regulated pathways in &#x201c;CP vs. Ctrl&#x201d; and &#x201c;ICA vs. CP&#x201d; at the protein and metabolite levels. One of the significant protein pathways in both &#x201c;CP vs. Ctrl&#x201d; (<italic>p</italic> &#x3d; 0.0110) and &#x201c;ICA vs. CP&#x201d; (<italic>p</italic> &#x3d; 0.0159) was the Protein digestion and absorption, highting the central role of this protein metabolism pathway (<xref ref-type="sec" rid="s11">Supplementary Tables S10, S11</xref>). The key metabolic pathways such as Glutathione metabolism (&#x201c;CP vs. Ctrl&#x201d;: <italic>p</italic> &#x3d; 0; &#x201c;ICA vs. CP&#x201d;: <italic>p</italic> &#x3d; 1 &#xd7; 10<sup>&#x2013;4</sup>), Arginine and proline metabolism (&#x201c;CP vs. Ctrl&#x201d;: <italic>p</italic> &#x3d; 0; &#x201c;ICA vs. CP&#x201d;: <italic>p</italic> &#x3d; 1 &#xd7; 10<sup>&#x2013;4</sup>), ABC transporters (&#x201c;CP vs. Ctrl&#x201d;: <italic>p</italic> &#x3d; 0; &#x201c;ICA vs. CP&#x201d;: <italic>p</italic> &#x3d; 0.0021), and Choline metabolism in cancer (&#x201c;CP vs. Ctrl&#x201d;: <italic>p</italic> &#x3d; 6 &#xd7; 10<sup>&#x2013;4</sup>; &#x201c;ICA vs. CP&#x201d;: <italic>p</italic> &#x3d; 3 &#xd7; 10<sup>&#x2013;4</sup>) were also almost the top ranked pathways.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>CP was a traditional drug that was primarily used in the treatment of various diseases, including cancer (<xref ref-type="bibr" rid="B7">Feng et al., 1972</xref>). However, the extreme cytotoxicity and side effects, such as reproductive toxicity in humans and animals, raise many concerns because infertility has a significant physical and emotional impact on the decision to use this medicine, particularly among young people (<xref ref-type="bibr" rid="B26">Rezvanfar et al., 2008</xref>; <xref ref-type="bibr" rid="B25">Pavin et al., 2018</xref>). Icariin, the main active constituent extracted from the traditional herb Epimedium, has been shown to have anti-oxidative, anti-inflammatory, and anti-apoptotic properties. It is now being considered as a potential therapeutic agent for a wide range of disorders, including reproductive system protection (<xref ref-type="bibr" rid="B14">He et al., 2020</xref>).</p>
<p>Based on CP-induced spermatogenesis dysfunction mouse models, we demonstrated that ICA has a testis protection effect. ICA effectively alleviated CP-induced testis injury in mice by regulating the expression of Purine metabolism, the PI3K-Akt signaling pathway, necroptosis, the mTOR signaling pathway, glycophospholipid metabolism, the FoxO signaling pathway, the AMPK signaling pathway, and ABC transporters, as well as reducing the severity of the testis tissue pathology change.</p>
<sec id="s4-1">
<title>ICA protects against CP-induced spermatogonia injury in mice</title>
<p>Previous research has shown that CP can harm testicular morphology through oxidative damage (<xref ref-type="bibr" rid="B33">Wang et al., 2021</xref>), suppressed spermatogenesis (<xref ref-type="bibr" rid="B22">&#xd6;zbilgin et al., 2021</xref>), decreased sperm quality (<xref ref-type="bibr" rid="B24">Park et al., 2021</xref>), and significant seminiferous tubule morphology injury (<xref ref-type="bibr" rid="B35">Zhang et al., 2021</xref>). The macroscopic and microscopic changes in the testis in the CP group were consistent with previous findings, including abnormal testicular development, reduced testicular volumes and organ ratios, significantly lower sperm count, and spermatogonia cell ultrastructure damage. However, administration of ICA resulted in a significant reduction in testicular injury caused by CP, as well as an increase in sperm count and spermatogonia structure.</p>
<p>Previous research has suggested that the damaging effect of CP on testicular germ cells may reduce sperm count (<xref ref-type="bibr" rid="B27">Shittu et al., 2019</xref>; <xref ref-type="bibr" rid="B13">Hai et al., 2021</xref>). In our study, we discovered that the number of abnormal sperm and the rate of sperm deformity increased significantly, which was consistent with previous research findings. Furthermore, when compared to the CP group, ICA could reduce the rate of sperm abnormality and increase sperm count. These findings suggested that ICA could reduce testicular injury caused by CP and protect sperm. To better understand the underlying mechanism, we stained testis tissue with H&#x26;E, which revealed that the number of cells in the seminiferous tubules was reduced and large lumens existed. Whereas a higher count of spermatozoa was found in the tubules of CP-treated mice given ICA. Furthermore, TEM results revealed that spermatogonia necrosis and apoptosis were significantly higher in the CP group than in the control and ICA groups. As a result, we hypothesized that ICA could reduce CP-induced testicular changes by inhibiting spermatogonia necrosis and apoptosis.</p>
</sec>
<sec id="s4-2">
<title>Integrated multi-omic analysis revealed the molecular mechanism of the protective efficiency of ICA on CP-induced testicular injury</title>
<p>We identified 1393 differentially expressed proteins in testis tissue from the Ctrl, CP, and ICA groups based on proteome results. We discovered that these proteins are involved in a variety of biological processes, including monosaccharide transport and metabolism, nucleotide biosynthetic process, monosaccharide metabolic process, ligase activity, and ATP-dependent activity, all of which are required for normal physiological functions in cells. Furthermore, metabonomics findings show that the differential metabolites from three groups were significantly enriched in Sphingolipid metabolism, Alanine, aspartate, and glutamate metabolism, Glutathione metabolism, and Arginine and proline metabolism pathways. To identify the key pathway of ICA in the treatment of spermatogenesis dysfunction in mice, we examined the most significantly enriched pathways in the proteome and metabolome, which included the PI3K-Akt signaling pathway, necroptosis, the mTOR signaling pathway, glycophospholipid metabolism, and ABC transporters.</p>
<p>Cell survival, growth, proliferation, angiogenesis, transcription, translation, and metabolism are all regulated by the PI3K-Akt/mTOR signaling pathway (<xref ref-type="bibr" rid="B6">Ediriweera et al., 2019</xref>; Tewari, Patni, Bishayee, Sah, Bishayee). The dysregulated PI3K-Akt/mTOR signaling pathway has been reported as the most frequently altered signaling pathway in male infertility, making it one of the most important signaling pathways for therapeutic intervention in male infertility (<xref ref-type="bibr" rid="B34">Wu et al., 2020</xref>; <xref ref-type="bibr" rid="B19">Long et al., 2021</xref>). HSP90, PP2A, Casp9, mTOR, SLC7A5, LPR5/6, ERK1/2, and Grb10 protein levels were activated in CP-induced spermatogenesis dysfunction testes, which were required for PI3K-Akt/mTOR activation. However, ICA effectively modified these key markers of the PI3K-Akt/mTOR pathway, causing them to return to normal levels in the testes after ICA treatment.</p>
<p>Necroptosis is a cellular response to environmental stress that can be caused by chemical and mechanical injury, inflammation, or infection. It differs from apoptosis in several ways, and previous research has linked it to a variety of diseases (<xref ref-type="bibr" rid="B12">Gong et al., 2019</xref>; <xref ref-type="bibr" rid="B16">Khoury et al., 2020</xref>). The activation of HSP90 and USP21, which leads to the activation of receptor-interacting protein kinase 1 (RIPK1), can cause necroptosis (<xref ref-type="bibr" rid="B21">Moln&#xe1;r et al., 2019</xref>). ICA inhibited RIPK1 by suppressing the expression of HSP90 and USP21, and it effectively blocked necroptosis in spermatogonia. ABC transporters are primary transporters found in all domains of life that couple the energy stored in ATP to the translocation of divese molecules across the membrane (<xref ref-type="bibr" rid="B4">Beis, 2015</xref>). ABCB1, ABCB8, ABCB11, and ABCG2 transporters protect various organs from toxic insult (<xref ref-type="bibr" rid="B18">Locher, 2016</xref>). CP significantly reduced the expression levels of ABCB1, ABCB8, ABCB9, ABCB10, and ABCB11. ICA increased the proten levels of these transporters, preventing testicular spermatogonia cell injury. Glycerophospholipids are the most common type of lipid found in mammalian cell membranes and play an important role in cellular functions such as signal transduction and protein function (<xref ref-type="bibr" rid="B18">Locher, 2016</xref>). Furthermore, CP disrupts the glycerophospholipids metabolism pathway in the testis, whereas ICA significantly promotes the addition of glycerophospholipids metabolism. Furthermore, enrichment analysis of metabolic and proteic pathways revealed that glycerophospholipid metabolism is a potential target metabolic pathway for ICA intervention in CP-induced spermatogenesis dysfunction in mice.</p>
<p>In conclusion, we used proteomic and metabolomic analysis to investigate the pharmacodynamic properties of ICA in alleviating CP-induced acute testis injury. The main finding of this study is that ICA protects against spermatogonia injury by influencing the expression of related proteins in CP-induced spermatogenesis dysfunction in mice <italic>via</italic> the pathways of PI3K-Akt signaling, Necroptosis, mTOR signaling, Glycerophospholipid metabolism, and ABC transporters. These findings support the idea that icariin can help with CP-induced testicular dysfunction. Furthermore, our findings point to novel mechanisms of action for icariin. Our findings are significant for future research into the molecular mechanisms underlying the use of ICA in the prevention of CP-induced testicular dysfunction in men.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are publicly available. This data can be found here: <ext-link ext-link-type="uri" xlink:href="https://www.iprox.cn/page/PSV023.html;?url=1670294860248KOpS">https://www.iprox.cn/page/PSV023.html;&#x003F;url&#x003D;1670294860248KOpS</ext-link>. Accession number: IPX0005509000.</p>
</sec>
<sec id="s6">
<title>Ethics statement</title>
<p>The animal study was reviewed and approved by the Hospital of Chengdu University of Traditional Chinese Medicine.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>CF and YuY designed the project. CF, YuY, YaY, and FY performed the experiment. CF, YuY, DC, and YaY wrote the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This research was funded by the National Natural Science Foundation of China (No. 81973866) and the Chengdu University of Traditional Chinese Medicine&#x2019;s Xinglin scholar discipline promotion talent program (No. BSH2021018).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.1040544/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2022.1040544/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material>
<label>Supplementary Figure S1</label>
<caption>
<p>Johnsen score of testes in different groups.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S2</label>
<caption>
<p>PCA of proteomic data for each group.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S3</label>
<caption>
<p>The Venn diagram shows the overlap between different protein groups.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S4</label>
<caption>
<p>OPLS-DA score plots. On the left are positive ions, and on the right are negative ions. <bold>(A)</bold> &#x201c;Ctrl vs. CP&#x201d;, <bold>(B)</bold> &#x201c;CP vs. ICA&#x201d;, <bold>(C)</bold> &#x201c;Ctrl vs. ICA&#x201d;.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S5</label>
<caption>
<p>Verification of differentially expressed genes by RT-PCR, &#x2a;<italic>p</italic> &#x3c; 0.05; &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S1</label>
<caption>
<p>The expression trends of proteins in C4, C6, and C7.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S2</label>
<caption>
<p>The enriched GO terms of dysregulated proteins.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S3</label>
<caption>
<p>The enriched KEGG pathways of dysregulated proteins.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S4</label>
<caption>
<p>The dysregulated metabolites in Ctrl vs. CP.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S5</label>
<caption>
<p>The dysregulated metabolites in CP vs. ICA.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S6</label>
<caption>
<p>The dysregulated metabolites in Ctrl vs. ICA.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S7</label>
<caption>
<p>The KEGG enrichment of differentially expressed metabolites in Ctrl vs. CP.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S8</label>
<caption>
<p>The KEGG enrichment of differentially expressed metabolites in CP vs. ICA.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S9</label>
<caption>
<p>The KEGG enrichment of differentially expressed metabolites in Ctrl vs. ICA.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S10</label>
<caption>
<p>The KEGG enrichment of differentially expressed proteins and metabolites in Ctrl vs. CP.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S11</label>
<caption>
<p>The KEGG enrichment of differentially expressed proteins and metabolites in CP vs. ICA.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Table S12</label>
<caption>
<p>The primers used in this study.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image3.JPEG" id="SM1" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet4.CSV" id="SM2" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet6.XLS" id="SM3" mimetype="application/XLS" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet3.CSV" id="SM4" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet5.XLS" id="SM5" mimetype="application/XLS" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.JPEG" id="SM6" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image4.JPEG" id="SM7" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet11.XLSX" id="SM8" mimetype="application/XLSX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.JPEG" id="SM9" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image5.JPEG" id="SM10" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet8.CSV" id="SM11" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet9.CSV" id="SM12" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet10.XLSX" id="SM13" mimetype="application/XLSX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet7.CSV" id="SM14" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet12.XLSX" id="SM15" mimetype="application/XLSX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.CSV" id="SM16" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet2.CSV" id="SM17" mimetype="application/CSV" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilar-Mahecha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hales</surname>
<given-names>B. F.</given-names>
</name>
<name>
<surname>Robaire</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Chronic cyclophosphamide treatment alters the expression of stress response genes in rat male germ cells</article-title>. <source>Biol. Reprod.</source> <volume>66</volume>, <fpage>1024</fpage>&#x2013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1095/biolreprod66.4.1024</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>El-Maraghy</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Rizk</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Role of the KATP channel in the protective effect of nicorandil on cyclophosphamide-induced lung and testicular toxicity in rats</article-title>. <source>Sci. Rep.</source> <volume>25</volume> (<issue>5</issue>), <fpage>14043</fpage>. <pub-id pub-id-type="doi">10.1038/srep14043</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balow</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>H. A.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Tsokos</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Antonovych</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Klippel</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>NIH conference</article-title>. <source>Lupus nephritis. Ann. Intern. Med.</source> <volume>106</volume>, <fpage>79</fpage>&#x2013;<lpage>94</lpage>.</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beis</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Structural basis for the mechanism of ABC transporters</article-title>. <source>Biochem. Soc. Trans.</source> <volume>43</volume> (<issue>5</issue>), <fpage>889</fpage>&#x2013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1042/BST20150047</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derosa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sahebkar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maffioli</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The role of various peroxisome proliferatoractivated receptors and their ligands in clinical practice</article-title>. <source>J. Cell. Physiol.</source> <volume>233</volume> (<issue>1</issue>), <fpage>153</fpage>&#x2013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.25804</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ediriweera</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Tennekoon</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Samarakoon</surname>
<given-names>S. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance</article-title>. <source>Semin. Cancer Biol.</source> <volume>59</volume>, <fpage>147</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.05.012</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Murkin</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Spicer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>B. S.</given-names>
</name>
<etal/>
</person-group> (<year>1972</year>). <article-title>Cyclophosphamide and infertility</article-title>. <source>Lancet</source> <volume>1</volume> (<issue>7755</issue>), <fpage>840</fpage>&#x2013;<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(72)90819-7</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fusco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Salinaro</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Siracusa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>D&#x27;Amico</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Impellizzeri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Scuto</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hidrox&#xae; counteracts cyclophosphamide-induced male infertility through NRF2 pathways in a mouse model</article-title>. <source>Antioxidants (Basel).</source> <volume>10</volume> (<issue>5</issue>), <fpage>778</fpage>. <pub-id pub-id-type="doi">10.3390/antiox10050778</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Futschik</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Carlisle</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Noise-robust soft clustering of gene expression time-course data</article-title>. <source>J. Bioinform. Comput. Biol.</source> <volume>3</volume> (<issue>4</issue>), <fpage>965</fpage>&#x2013;<lpage>988</lpage>. <pub-id pub-id-type="doi">10.1142/s0219720005001375</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghobadi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moloudizargari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asghari</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Abdollahi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source> <volume>13</volume> (<issue>5</issue>), <fpage>525</fpage>&#x2013;<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1080/17425255.2017.1277205</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghobadi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moloudizargari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asghari</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Abdollahi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source> <volume>13</volume> (<issue>5</issue>), <fpage>525</fpage>&#x2013;<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1080/17425255.2017.1277205</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The role of necroptosis in cancer biology and therapy</article-title>. <source>Mol. Cancer</source> <volume>18</volume> (<issue>1</issue>), <fpage>100</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-019-1029-8</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hai</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>Y. N.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Protective effects of sesamin on cytoxan-induced spermatogenesis dysfunction by regulating RNF8-ubH2A/ubH2B pathways in male mice</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>708467</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.708467</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Pharmacological effects of icariin</article-title>. <source>Adv. Pharmacol.</source> <volume>87</volume>, <fpage>179</fpage>&#x2013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apha.2019.10.004</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kern</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Kehrer</surname>
<given-names>J. P.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Acrolein-induced cell death: A caspase-influenced decision between apoptosis and oncosis/necrosis</article-title>. <source>Chem. Biol. Interact.</source> <volume>139</volume>, <fpage>79</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/s0009-2797(01)00295-2</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoury</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Necroptosis in the pathophysiology of disease</article-title>. <source>Am. J. Pathol.</source> <volume>190</volume> (<issue>2</issue>), <fpage>272</fpage>&#x2013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2019.10.012</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Icariin inhibits TNF-&#x3b1;/IFN-&#x3b3; induced inflammatory response via inhibition of the substance P and p38-MAPK signaling pathway in human keratinocytes</article-title>. <source>Int. Immunopharmacol.</source> <volume>29</volume>, <fpage>401</fpage>&#x2013;<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2015.10.023</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Locher</surname>
<given-names>K. P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Mechanistic diversity in ATP-binding cassette (ABC) transporters</article-title>. <source>Nat. Struct. Mol. Biol.</source> <volume>23</volume> (<issue>6</issue>), <fpage>487</fpage>&#x2013;<lpage>493</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.3216</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Retinoic acid can improve autophagy through depression of the PI3K-Akt-mTOR signaling pathway via RAR&#x3b1; to restore spermatogenesis in cryptorchid infertile rats</article-title>. <source>Genes. Dis.</source> <volume>9</volume> (<issue>5</issue>), <fpage>1368</fpage>&#x2013;<lpage>1377</lpage>. <pub-id pub-id-type="doi">10.1016/j.gendis.2021.03.006</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludeman</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>The chemistry of the metabolites of cyclophosphamide</article-title>. <source>Curr. Pharm. Des.</source> <volume>5</volume>, <fpage>627</fpage>&#x2013;<lpage>643</lpage>.</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moln&#xe1;r</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>M&#xe1;zl&#xf3;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tslaf</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sz&#xf6;ll&#x151;si</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Emri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Koncz</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Current translational potential and underlying molecular mechanisms of necroptosis</article-title>. <source>Cell. Death Dis.</source> <volume>10</volume> (<issue>11</issue>), <fpage>860</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-2094-z</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#xd6;zbilgin</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Demir&#xf6;ren</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>&#xdc;&#xe7;&#xf6;z</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oztatlici</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cyclophosphamide suppresses spermatogenesis in the testis of mice through downregulation of miR-34b and miR-34c</article-title>. <source>Andrologia</source> <volume>53</volume> (<issue>7</issue>), <fpage>e14071</fpage>. <pub-id pub-id-type="doi">10.1111/and.14071</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagnoux</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Updates in ANCA-associated vasculitis</article-title>. <source>Eur. J. Rheumatol.</source> <volume>3</volume>, <fpage>122</fpage>&#x2013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.5152/eurjrheum.2015.0043</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Modified MYOMI-14 Korean herbal formulations have protective effects against cyclophosphamide-induced male infertility in mice</article-title>. <source>Andrologia</source> <volume>53</volume> (<issue>5</issue>), <fpage>e14025</fpage>. <pub-id pub-id-type="doi">10.1111/and.14025</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavin</surname>
<given-names>N. F.</given-names>
</name>
<name>
<surname>Izaguirry</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Spiazzi</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Mendez</surname>
<given-names>A. S. L.</given-names>
</name>
<name>
<surname>Leivas</surname>
<given-names>F. G.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Tribulus terrestris protects against male reproductive damage induced by cyclophosphamide in mice</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2018</volume>, <fpage>5758191</fpage>. <pub-id pub-id-type="doi">10.1155/2018/5758191</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezvanfar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sadrkhanlou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ahmadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shojaei-Sadee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rezvanfar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohammadirad</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress</article-title>. <source>Hum. Exp. Toxicol.</source> <volume>27</volume>, <fpage>901</fpage>&#x2013;<lpage>910</lpage>. <pub-id pub-id-type="doi">10.1177/0960327108102046</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shittu</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Shittu</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Akindele</surname>
<given-names>O. O.</given-names>
</name>
<name>
<surname>Kunle-Alabi</surname>
<given-names>O. T.</given-names>
</name>
<name>
<surname>Raji</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Protective action of N-acetylcysteine on sperm quality in cyclophosphamide-induced testicular toxicity in male wistar rats</article-title>. <source>JBRA Assist. Reprod.</source> <volume>23</volume> (<issue>2</issue>), <fpage>83</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.5935/1518-0557.20180079</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Icariin protects mouse Leydig cell testosterone synthesis from the adverse effects of di(2-ethylhexyl) phthalate</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>378</volume>, <fpage>114612</fpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2019.114612</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kioka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fukuhara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kuribayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Asano</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Visualization of spatial distribution of spermatogenesis in mouse testes using creatine chemical exchange saturation transfer imaging</article-title>. <source>J. Magn. Reson. Imaging.</source> <volume>54</volume> (<issue>5</issue>), <fpage>1457</fpage>&#x2013;<lpage>1465</lpage>. <pub-id pub-id-type="doi">10.1002/jmri.27734</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tewari</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Patni</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bishayee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sah</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Bishayee</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy</article-title>. <source>Semin. Cancer Biol.</source> <volume>80</volume>, <fpage>1</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.12.008</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trasler</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Robaire</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Effects of cyclophosphamide on selected cytosolic and mitochondrial enzymes in the epididymis of the rat</article-title>. <source>J. Androl.</source> <volume>9</volume>, <fpage>142</fpage>&#x2013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1002/j.1939-4640.1988.tb01026.x</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vernet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aitken</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Drevet</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Antioxidant strategies in the epididymis</article-title>. <source>Mol. Cell. Endocrinol.</source> <volume>216</volume>, <fpage>31</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2003.10.069</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Lepidium draba L. leaves extract ameliorated cyclophosphamide-induced testicular toxicity by modulation of ROS-dependent Keap1/Nrf2/HO1, Bax/Bcl2/p53/caspase-3, and inflammatory signaling pathways</article-title>. <source>J. Food Biochem.</source> <volume>45</volume> (<issue>12</issue>), <fpage>e13987</fpage>. <comment>Epub 2021 Nov 3. PMID: 34730245</comment>. <pub-id pub-id-type="doi">10.1111/jfbc.13987</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Effect and mechanism of PI3K/AKT/mTOR signaling pathway in the apoptosis of GC-1 cells induced by nickel nanoparticles</article-title>. <source>Chemosphere</source> <volume>255</volume>, <fpage>126913</fpage>. <pub-id pub-id-type="doi">10.1016/j.chemosphere.2020.126913</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Network pharmacology reveals pharmacological effect and mechanism of Panax notoginseng (Burk.) F. H. Chen on reproductive and genetic toxicity in male mice</article-title>. <source>J. Ethnopharmacol.</source> <volume>270</volume>, <fpage>113792</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.113792</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>